EcoR1 Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

EcoR1 Capital’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$156M	Hold	4,288,120	–	–	6.61%	5
2025 Q4	$200M	Hold	4,288,120	–	–	9.06%	4
2025 Q3	$179M	Hold	4,288,120	–	–	8.57%	5
2025 Q2	$123M	Hold	4,288,120	–	–	7.3%	5
2025 Q1	$144M	Hold	4,288,120	–	–	8.53%	5
2024 Q4	$219M	Hold	4,288,120	–	–	8.29%	3
2024 Q3	$219M	Buy	4,288,120 +132,745	+3%	+$6.85M	7.5%	3
2024 Q2	$186M	Hold	4,155,375	–	–	5.69%	5
2024 Q1	$195M	Buy	4,155,375 +2,142,858	+106%	+$83.8M	4.92%	5
2023 Q4	$71.6M	Buy	2,012,517 +482,254	+32%	+$14.8M	1.86%	15
2023 Q3	$45.5M	Buy	1,530,263 +200,000	+15%	+$4.12M	1.54%	15
2023 Q2	$24M	Hold	1,330,263	–	–	0.59%	25
2023 Q1	$21.4M	Hold	1,330,263	–	–	0.69%	25
2022 Q4	$24.3M	Hold	1,330,263	–	–	0.74%	26
2022 Q3	$26.1M	Hold	1,330,263	–	–	0.77%	27
2022 Q2	$24.8M	Buy	1,330,263 +540,054	+68%	+$10.8M	0.86%	26
2022 Q1	$17.3M	Buy	790,209 +200,040	+34%	+$4.05M	0.54%	36
2021 Q4	$16.8M	Buy	+590,169	New	+$14.5M	0.53%	29
2020 Q3	–	Sell	-859,802	Closed	-$15.1M	–	51
2020 Q2	$15.1M	Buy	859,802 +509,802	+146%	+$8.69M	1.11%	25
2020 Q1	$5.14M	Buy	+350,000	New	+$7.17M	0.54%	33

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

EcoR1 Capital's CRNX Position: Q1 2026 in Review

EcoR1 Capital held its Crinetics Pharmaceuticals (CRNX) position steady in Q1 2026 at 4,288,120 shares worth $156M. The position accounts for 6.61% of the portfolio, ranked #5.

EcoR1 Capital first reported a position in CRNX in Q1 2020 and has held it in 20 quarters since. The position peaked at $219M in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

EcoR1 Capital held 4,288,120 shares of Crinetics Pharmaceuticals worth $156M as of Q1 2026.
EcoR1 Capital left its Crinetics Pharmaceuticals share count unchanged in Q1 2026.
Crinetics Pharmaceuticals made up 6.61% of EcoR1 Capital's portfolio in Q1 2026, its #5 holding.
EcoR1 Capital first reported a position in Crinetics Pharmaceuticals in Q1 2020 and has held it in 20 quarters since.
EcoR1 Capital's Crinetics Pharmaceuticals position peaked at $219M in Q4 2024.
243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on EcoR1 Capital's 13F filing for Q1 2026, filed 15 May 2026.